Plain-English translation of NCT05626920 on ClinicalTrials.gov โ ยท Source last updated ยท Translation generated ยท How we translate trials
Phase 1/2 โ A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This study is testing whether a medication called disulfiram can help preserve vision in people with inherited retinal degeneration โ a group of genetic eye diseases that progressively damage the retina and cause vision loss. In lab studies, blocking a certain chemical pathway in the eye has improved vision in animal models of retinal disease. Researchers believe disulfiram, which is already approved by the FDA for other uses, may work the same way in humans.
Inherited retinal diseases currently have no cure, and vision loss is progressive and irreversible. This medication targets a specific biological pathway that researchers believe contributes to further vision damage, offering a potential new treatment option for people with these conditions.
You likely qualify ifโฆ
You likely don't qualify ifโฆ
You will be randomly assigned to receive either disulfiram or a placebo (inactive pill) for several months. The study involves visiting the research clinic for eye exams, vision testing, and blood work to check your liver function. You must completely avoid alcohol throughout the study and for 2 weeks before and after. The entire study lasts about 8 months, and you will need to remain in the area for the duration of your participation.
AI-generated summary from trial data ยท Oct 7, 2026 ยท Not medical advice
United States